

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 9516-058-999 (CAM No. 501872-999057)	APPLICATION NO. 10/535,004
	APPLICANT: Muller et al.	
	FILING DATE: May 11, 2005	ART UNIT: CONF. NO.: TBA 9094

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01			
	A02			
	A03			
	A04			
	A05			
	A06			

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
					YES	NO
	B01					
	B02					
	B03					
	B04					

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)				
RP	C11	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-673			
	C12	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," Crit. Rev. Immunol. 22(5-6):425-437			
	C13	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," Expert Opin. Biol. Ther. 2(8):953-966			
	C14	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," Cancer Res. 63(23):8073-8078			
	C15	MARRIOTT et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," Expert Opin. Biol. Ther. 1(4):1-8			
	C16	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," Clin. Exp. Immunol. 130(1):75-84			
	C17	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," Br. J. Haematol. 124(3):366-375			
RP	C18	MULLER et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg. Med. Chem. Lett. 9(11):1625-1630			

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

9516-058-999

APPLICATION NO.

10/535,004

APPLICANT

Muller et al.

FILING DATE

May 11, 2005

GROUP

To Be Assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
[Handwritten Initials]	A01	09/642,557		Bennett et al. (10624-046-999)			08-18-00
	A02	10/316,673		Muller et al. (9516-194-999)			12-11-02
	A03	10/748,085		Man et al. (9516-084-999)			12-29-03
	A04	10/900,270		Muller et al. (9516-323-999)			07-28-04
	A05	10/900,332		Muller et al. (9516-324-999)			07-28-04
	A06	60/454,155		Muller et al. (9516-098-888)			03-12-03
	A07	60/454,149		Man et al. (9516-099-888)			03-12-03
	A08	60/452,460		Muller et al. (9516-088-888)			03-05-03
	A09	60/438,450		Muller et al. (9516-065-888)			01-07-03
	A10	60/438,448		Muller et al. (9516-064-888)			01-07-03
	A11	60/436,975		Muller et al. (9516-084-888)			12-30-02
	A12	60/427,379		Muller et al. (9516-058-888)			11-18-02
	A13	2005/0014727	01-20-05	Muller et al.			
	A14	2004/0167199	08-26-04	Muller et al.			
	A15	2004/0167174	08-26-04	Man et al.			
	A16	2004/0147588	07-29-04	Man et al.			
	A17	2004-0127536	07-01-04	Bhagwat et al.			
	A18	2004/006096	01-08-04	Muller et al.			
	A19	2004-0029832	02-12-04	Zeldis			
	A20	2004/0019106	01-29-04	Muller et al.			
	A21	2003-0220330	11-27-03	Satoh et al.			
	A22	2003/0187052	10-02-03	Muller et al.			
	A23	2003-0073732	04-17-03	Sakata et al.			
	A24	2003/0045726	03-06-03	Muller			
	A25	2002-0103229	08-01-02	Bhagwat et al.			
	A26	3,536,809	10-27-70	Appiezweig			
	A27	3,598,123	08-10-71	Zaffaroni			
	A28	3,845,770	11-05-74	Theeuwes et al.			
	A29	3,916,899	11-04-75	Theeuwes et al.			
	A30	4,008,719	02-22-77	Theeuwes et al.			
	A31	5,059,595	10-22-91	La Grazie			
A32	5,073,543	12-17-91	Marshall et al.				
A33	5,120,548	06-09-92	McClelland et al.				

22	A34	5,354,556	10-11-94	Sparks et al.			
	A35	5,463,063	10-31-95	Muller			
	A36	5,591,767	01-07-97	Mohr et al.			
	A37	5,605,914	02-25-97	Muller			
	A38	5,632,984	05-27-97	Wong et al.			
	A39	5,635,517	06-03-97	Muller et al.			
	A40	5,639,476	06-17-97	Oshlack et al.			
	A41	5,658,940	08-19-97	Muller et al.			
	A42	5,674,533	10-07-97	Santus et al.			
	A43	5,698,579	12-16-97	Muller			
	A44	5,703,098	12-30-97	Muller			
	A45	5,728,844	03-17-98	Muller			
	A46	5,728,845	03-17-98	Muller			
	A47	5,733,566	03-31-98	Lewis			
	A48	5,736,570	04-07-98	Muller			
	A49	5,770,589	06-23-98	Billson			
	A50	5,798,368	08-25-98	Muller et al.			
	A51	5,801,195	09-01-98	Muller et al.			
	A52	5,877,200	03-02-99	Muller			
	A53	5,929,117	07-27-99	Muller et al.			
	A54	5,955,476	09-21-99	Muller et al.			
	A55	5,968,945	10-19-99	Muller et al.			
	A56	6,001,368	12-14-99	Jenks			
	A57	6,011,050	01-04-00	Muller et al.			
	A58	6,015,803	01-18-00	Wirostko			
	A59	6,020,358	01-04-00	Muller et al.			
	A60	6,046,221	04-04-00	Muller et al.			
	A61	6,075,041	06-13-00	Muller			
	A62	6,130,226	10-10-00	Muller et al.			
	A63	6,180,644	01-30-01	Muller et al.			
	A64	6,200,987	03-13-01	Muller			
	A65	6,214,857	04-10-01	Muller et al.			
	A66	6,218,369	04-17-01	Bombardelli et al.			
	A67	6,225,348	05-01-01	Paulson			
	A68	6,262,101	07-17-01	Muller et al.			
	A69	6,281,230	08-28-01	Muller et al.			
	A70	6,284,780	09-04-01	Muller et al.			
	A71	6,326,388	12-04-01	Man et al.			
	A72	6,380,239	04-30-02	Muller et al.			
	A73	6,395,754	05-28-02	Muller et al.			
	A74	6,403,613	06-11-02	Man et al.			
23	A75	6,429,221	08-06-02	Muller et al.			

RP	A76	6,458,810	10-01-02	Muller et al.			
	A77	6,479,554	11-12-02	Muller et al.			
	A78	6,518,281	02-11-03	Muller et al.			
	A79	6,656,964	12-02-03	Muller et al.			
	A80	6,667,316	12-23-04	Man et al.			
	A81	6,699,899	03-02-04	Man et al.			
	A82	6,844,359	01-18-05	Muller			
	A83	6,897,231	05-24-05	Bhagwat et al.			
RP	A84	6,911,464	06-28-05	Man et al.			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
RP	B01	WO 95/01348	01-12-95	PCT				
	B02	WO 97/08143	03-06-97	PCT				
	B03	WO 97/23457	07-03-97	PCT				
	B04	WO 99/06041	02-11-99	PCT				
	B05	WO 01/34606	05-17-01	PCT				
	B06	WO 01/45702	06-28-01	PCT				
	B07	WO 03/080048	10-02-03	PCT				
RP	B08	WO 03/080049	10-02-03	PCT				

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

RP	C01	Beavo et al., 1990, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors," Trends Pharmacol. Sci. 11(4):150-155
	C02	Cartensen, 1995, Drug Stability: Principles & Practice, 2 <sup>nd</sup> ed., Marcel Dekker, New York, NY pp. 379-380
	C03	Corral, L.G. et al., Ann. Rheum. Dis. 58:(Suppl I) 1107-1113 (1999)
	C04	Hidaka et al., 1976, "Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase," Biochim. Biophys. Acta. 429(2):485-497
	C05	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," Bioorg. Med. Chem. Lett. 8(19):2669-2674
	C06	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240
	C07	Nicholson et al., 1991, "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes," Trends. Pharmacol. Sci. 12(1):19-27
	C08	Wilens, 1972, Tables of Resolving Agents and Optical Resolutions, Eliel, ed., Univ. Notre Dame Press, Notre Dame, IN, pp. 268
	C09	Wilens et al., 1977, Tetrahedron 33:2725
RP	C10	Wolff, ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5 <sup>th</sup> ed., 172-178, 949-982

EXAMINER

DATE CONSIDERED

7/31/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.